BioCryst Announces Initiation Of Phase II Study Of Intramuscular Peramivir For The Treatment Of Seasonal Influenza

 11.07.2008 05:15   medicalnewstoday.com

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the initiation of a Phase II study of intramuscular (i.m.) peramivir for the treatment of seasonal influenza. The double-blind, placebo-controlled, parallel group Phase II trial will compare the efficacy of a single 600 mg injection of i.m. peramivir to placebo in the treatment of seasonal influenza.

World SARS